에 대한 최신 뉴스 BioNTech (NASDAQ:BNTX) 주식

BIONTECH SE-ADR

BioNTech

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.

vaccine-4892059

News

Movers

BNTX

MRNA

화요일(20일) 백신 관련 주식이 상승세를 보였다. 이는 미국 식품의약국(FDA)에서 공개된 문서에 따르면 해당 기관의 자문위원회가 이번 주에 회의를 개최할 예정이기 때문이다. 

모더나·바이오엔테크 등 백신주, 화요일에 급등한 이유는?

Indianapolis,-,Circa,November,2021:,Eli,Lilly,And,Company,World

Earnings

Equities

Large Cap

AFRM

ARGX

DASH

MMYT

REGN

SMMT

VRTX

지난주 가장 저조한 성과를 기록한 대형주는 다음과 같다. 일라이 릴리, 어펌 홀딩스, 리제네론, 아겐스, 버텍스 파마슈티컬스, 서밋 테라퓨틱스, 메이크마이트립, 바이오엔테크, FNF, 오로라, 도어대시

일라이릴리·어펌홀딩스·리제네론 등 지난주 급락한 대형주 12종목 (5월 5일~9일)

Market,Sentiment,,Fear,And,Greed,Index,,Emotional,On,Stock,Market

Pre-Market Outlook

Markets

Trading Ideas

APEI

ORCL

CNN 머니 공포·탐욕 지수는 전체 시장 심리가 개선된 모습을 나타냈지만, 지수는 금요일에도 여전히 &#34;극단적 공포&#34; 영역에 머물렀다.

다우 200p 이상 올랐으나 주간 하락 기록: 탐욕 지수는 여전히 &#39;극단적 공포&#39; 영역

BioNTech SE

Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) has outperformed the market over the past 15 years by 2.91% on an annualized basis producing an average annual return of 14.61%. Currently, Elevance Health has a market capitalization of $90.40 billion. 
Buying $1000 In ELV: If an investor had bought $1000 of ELV stock 15 years ago, it would be worth $7,862.45 today based on a price of $400.12 for ELV at the time of writing.
<h3>Elevance Health's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747867524_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

$1000 Invested In Elevance Health 15 Years Ago Would Be Worth This Much Today

"At some point you have to be financially responsible," luxury watch collector Olivier Paredes told <a href="https://www.businessinsider.com/middle-class-economy-wealth-luxury-shopping-consumers-spending-retail-2025-5">Business Insider</a> in early May. He was sharing why he&#8217;s stepping back from his five-year habit of splurging on luxury watches.&nbsp;
Sudden price hikes doubled tags on brands like Rolex and Omega, popping the pandemic-era spending bubble and driving a record 50 million aspirational shoppers out of the roughly $392 billion personal luxury goods market.
<h2 class="wp-block-heading">Why The Bubble Popped</h2>
The global personal luxury goods market shrank 2% year-over-year in 2024, according to a <a href="https://www.bain.com/insights/luxury-in-transition-securing-future-growth">Bain &amp; Co. report</a>, marking its first contraction in 15 years, excluding the COVID-19 pandemic period.
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
In 2024, global luxury spending remained steady at approximately €1.5 trillion ($1.7 trillion), marking one of the weakest years since the Great Recession, according to <a href="https://www.bain.com/insights/luxury-in-transition-securing-future-growth">Bain</a>. As a result, the personal luxury goods market dipped to €363 billion, reflecting a 2% decline compared to 2023 at current exchange rates, though flat at constant exchange rates.&nbsp;
Over the past two years, the global luxury customer base has shrunk by about 50 million consumers, driven by economic uncertainty, elevated prices, and reduced engagement from younger generations.
<h2 class="wp-block-heading">Middle-Income Retreat</h2>
Middle-income households—defined by <a href="https://www.pewresearch.org/short-reads/2024/09/16/are-you-in-the-american-middle-class/#:~:text=We%20use%20your%20size%2Dadjusted,and%20expressed%20in%202022%20dollars.)">Pew Research Center</a> as those earning between $56,600 and $169,800 annually—have retrenched after pandemic-era YOLO spending surges.&nbsp;
<a href="https://www.businessinsider.com/middle-class-economy-wealth-luxury-shopping-consumers-spending-retail-2025-5">According to Business Insider,</a> one handbag enthusiast who used to shell out nearly $20,000 a year says she's trimmed her budget to $6,000, pointing to doubled sticker prices for top bag brands over the last five years.&nbsp;
Paredes himself poured about $70,000 into high-end timepieces over five years before deciding it was time to focus on more pressing financial goals.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a>
<h2 class="wp-block-heading">Price vs Paycheck</h2>
Over the past five years, <a href="https://www.bls.gov/regions/mid-atlantic/data/consumerpriceindexhistorical_us_table.htm?">U.S. consumer prices</a> have increased by about 25.5%, while average <a href="https://fred.stlouisfed.org/series/CES0500000003?utm">hourly wages </a>for private-sector workers have risen roughly 29.8%, according to federal data. Although wages have slightly outpaced <a href="https://www.bls.gov/cpi">inflation</a>, the gains have done little to ease the strain on discretionary budgets.&nbsp;&nbsp;
According to Primerica, <a href="https://investors.primerica.com/news-events/press-releases/detail/344/national-survey-middle-income-americans-grapple-with?utm">69% of middle-class consumers</a> feel their income is falling behind the cost of living, and 71% rate their ability to save for the future as "poor" or "not so good." Meanwhile, <a href="https://www.census.gov/retail/sales.html">U.S. retail sales </a>rose a scant 0.1% in April, underscoring consumer caution.
<h2 class="wp-block-heading">What's Next For Luxury</h2>
"We're finally seeing a limit to the ‘you only live once' urge to splurge," said Ted Rossman, senior industry analyst at Bankrate. In a recent <a href="https://www.bankrate.com/credit-cards/news/discretionary-spending-survey/">survey</a>, he noted that more than half of U.S. adults expect to reduce spending on discretionary items like travel, dining out, and entertainment—attributing the shift to fading post-pandemic demand and ongoing inflation.
This ties into a Feb. 9 <a href="https://www.mckinsey.com/featured-insights/themes/whats-next-for-luxury">McKinsey &amp; Co.</a> report revealing a sharp slowdown in the luxury market, even hitting top brands.&nbsp;
Read Next:
<ul class="wp-block-list">
<li>Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a></li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
Image: Shutterstock

Personal Finance

'At Some Point You Have To Be Financially Responsible' Says Luxury Watch Buyer As Market Loses 50 Million Shoppers

Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) has outperformed the market over the past 5 years by 1.82% on an annualized basis producing an average annual return of 16.1%. Currently, Energy Transfer has a market capitalization of $61.36 billion. 
Buying $1000 In ET: If an investor had bought $1000 of ET stock 5 years ago, it would be worth $2,109.26 today based on a price of $17.88 for ET at the time of writing.
<h3>Energy Transfer's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747866633_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Energy Transfer 5 Years Ago Would Be Worth This Much Today

Honeywell Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) has outperformed the market over the past 20 years by 1.51% on an annualized basis producing an average annual return of 9.75%. Currently, Honeywell Intl has a market capitalization of $142.74 billion. 
Buying $1000 In HON: If an investor had bought $1000 of HON stock 20 years ago, it would be worth $6,362.44 today based on a price of $221.90 for HON at the time of writing.
<h3>Honeywell Intl's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747865721_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Honeywell Intl 20 Years Ago Would Be Worth This Much Today

There could be plenty of good to come <a href="https://www.benzinga.com/topic/artificial-intelligence">from artificial intelligence,</a> including search results and fact-finding on the web.
While artificial intelligence can help write stories, a newspaper found out the hard way that it's important to check the work of a writer, even if it's a computer.
What Happened: The Chicago Sun-Times newspaper released a "Summer Reading lLst for 2025" as part of its "Best of Summer" section. The list ended up being made-up book titles from real authors and even later tricked Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)-owned <a href="https://www.benzinga.com/25/05/45536887/this-is-the-first-time-in-two-decades-that-google-is-extremely-vulnerableperplexitys-ceo-breaks-down-search-giants-margin-trap">Google search engine.</a>
The entire list was made up by using artificial intelligence, as <a href="https://www.404media.co/chicago-sun-times-prints-ai-generated-summer-reading-list-with-books-that-dont-exist/">reported </a>by 404 Media.
For example, a book on the list was titled "Tidewater" by Isabel Allende and included a description of the book.
The book list was written by Marco Buscaglia, according to the report.
"I do use AI for background at times but always check out the material first. This time, I did not and I can't believe I missed it because it's so obvious. No excuses," Buscaglia told 404 Media.
Buscaglia told 404 Media the error was on them "100 percent," and they were embarrassed by the mistake.
404 Media found that other sections of the Best of Summer Heat Index special featured AI-generated sections. Quotes from experts appear to be made up or from people who are not real experts in their respective fields.
"We are looking into how this made it into print as we speak. It is not editorial content and was not created by, or approved by, the Sun-Times newsroom. We value your trust in our reporting and take this very seriously," the newspaper, which is owned by non-profit Chicago Public Media, said on <a href="https://bsky.app/profile/chicago.suntimes.com/post/3lpmbre5edk2a?ref=404media.co">Bluesky</a>.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45548615/alphabet-well-positioned-for-google-search-dominance-analyst-says-can-navigate-the-shift-to-ai-search">Alphabet &#8216;Well Positioned&#8217; For Google Search Dominance: Analyst Says Can &#8216;Navigate The Shift To AI Search&#8217;</a>
Why It's Important: While many of the book titles and stories listed in the summer reading list were fake, web crawling done by Google search showed the books to be real.
404 Media shows a search for "Tidewater Dreams Isabel Allende" on Google. A previous search shows the AI Overview at the top of the search results to show that this title is a book by Isabel Allende, a collection of short stories. Allende is a real author. 
"The stories explore theme of love, loss, and the power of memory, often featuring strong female characters and a mystical, almost magical realism style," the description on Google reads.
Allende never wrote a book titled "Tidewater Dreams."
Searching for the same four words — "Tidewater Dreams Isabel Allende" — today reveals a much different result.
Google's new AI Mode says the search "likely refers to a fabricated book title that was included in an AI-generated summer reading list published in several newspapers."
Google says the book title is not a recognized literary work.
While Google has corrected the error in search results, the national newsletter publishing a fake list of books gave some credibility to the titles that helped them briefly appear in Google search results.
An important reminder that not everything you read on the internet is true and not everything that appears in Google searches is true. It's always important to check and verify sources and, in some cases, look for more than one source.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/top-stories/25/05/45498574/microsoft-stock-nears-record-high-as-ai-driven-layoffs-hit-hundreds-even-ai-director">Microsoft Stock Nears Record High As AI-Driven Layoffs Hit Hundreds — Even AI Director</a></li>
</ul>
Photo: fizkes via Shutterstock

Tech

Media

GOOG

GOOGL

Fake Books, Real Deception: How AI-Generated Summer Reading List Fooled Google, Readers

General

Weyerhaeuser Company To Sell Its Lumber Mill In Princeton, British Columbia, To The Gorman Group For ~$120M CAD

Providing a diverse range of perspectives from bullish to bearish, 36 analysts have published ratings on Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">13</td>
<td align="right">13</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">6</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $192.58, a high estimate of $240.00, and a low estimate of $159.00. A 6.01% drop is evident in the current average compared to the previous average price target of $204.89. 
<img src="https://www.benzinga.com/files/images/story/2025/1747864868_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Alphabet. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$189.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>Curtis Shauger</td>
<td>WestPark Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$240.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$220.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Stephen Ju</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$186.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Mark Shmulik</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$185.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$178.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$175.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$189.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Mark Kelley</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$192.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$159.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$178.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$178.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$185.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$195.00</td>
<td>$229.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$185.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>James Lee</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$205.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$167.00</td>
<td>$184.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Rohit Kulkarni</td>
<td>Roth MKM</td>
<td>Maintains</td>
<td>Buy</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$202.00</td>
<td>$220.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Alphabet. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Alphabet compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Alphabet's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Alphabet's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GOOGL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Alphabet analyst ratings.</a>
<h2>Delving into Alphabet's Background</h2>
Alphabet is a holding company that wholly owns internet giant Google. The California-based company derives slightly less than 90% of its revenue from Google services, the vast majority of which is advertising sales. Alongside online ads, Google services houses sales stemming from Google's subscription services (YouTube TV, YouTube Music among others), platforms (sales and in-app purchases on Play Store), and devices (Chromebooks, Pixel smartphones, and smart home products such as Chromecast). Google's cloud computing platform, or GCP, accounts for roughly 10% of Alphabet's revenue with the firm's investments in up-and-coming technologies such as self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) making up the rest.
<h3>Breaking Down Alphabet's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Alphabet's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 12.04%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Communication Services sector.
Net Margin: Alphabet's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 38.28% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Alphabet's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 10.3%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Alphabet's ROA stands out, surpassing industry averages. With an impressive ROA of 7.46%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.07.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

The Analyst Verdict: Alphabet In The Eyes Of 36 Experts

Across the recent three months, 5 analysts have shared their insights on Keysight Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $181.8, a high estimate of $190.00, and a low estimate of $172.00. Observing a 2.36% increase, the current average has risen from the previous average price target of $177.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1747864855_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Keysight Techs among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$177.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$172.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Richard Eastman</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Aaron Rakers</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Keysight Techs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Keysight Techs compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Keysight Techs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Keysight Techs's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/KEYS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Keysight Techs analyst ratings.</a>
<h2>All You Need to Know About Keysight Techs</h2>
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
<h3>Keysight Techs's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Keysight Techs's revenue growth over a period of 3M has been noteworthy. As of 31 January, 2025, the company achieved a revenue growth rate of approximately 3.1%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Keysight Techs's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 13.02%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Keysight Techs's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.28%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Keysight Techs's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.81%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.39.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KEYS

Beyond The Numbers: 5 Analysts Discuss Keysight Techs Stock

10 analysts have shared their evaluations of First Horizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $22.6, a high estimate of $25.00, and a low estimate of $20.00. Experiencing a 3.34% decline, the current average is now lower than the previous average price target of $23.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1747864847_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive First Horizon is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Chiaverini</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$25.00</td>
<td>-</td>
</tr>
<tr>
<td>John McDonald</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Hold</td>
<td>$21.00</td>
<td>-</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Brady Gailey</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Ebrahim Poonawala</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>David George</td>
<td>Baird</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Michael Rose</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Ben Gerlinger</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to First Horizon. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of First Horizon compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into First Horizon's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FHN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on First Horizon analyst ratings.</a>
<h2>Get to Know First Horizon Better</h2>
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer &amp; Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer &amp; Wealth. The Commercial, Consumer &amp; Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets.
<h3>Unraveling the Financial Story of First Horizon</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, First Horizon faced challenges, resulting in a decline of approximately -1.13% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 27.0%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): First Horizon's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.55%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.26%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: First Horizon's debt-to-equity ratio is below the industry average at 0.35, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 10 Analyst Ratings Have To Say About First Horizon

During the last three months, 9 analysts shared their evaluations of Columbia Banking System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Columbia Banking System and provided 12-month price targets. The average target is $28.11, accompanied by a high estimate of $32.00 and a low estimate of $25.00. Highlighting a 11.1% decrease, the current average has fallen from the previous average price target of $31.62. 
<img src="https://www.benzinga.com/files/images/story/2025/1747864839_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Columbia Banking System by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Chiaverini</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$27.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Clark</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$32.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Karl Shepard</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$27.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Jeff Rulis</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Christopher Mcgratty</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$30.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$29.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$27.00</td>
<td>$33.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Columbia Banking System. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Columbia Banking System compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Columbia Banking System's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Columbia Banking System's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/COLB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Columbia Banking System analyst ratings.</a>
<h2>Discovering Columbia Banking System: A Closer Look</h2>
Columbia Banking System Inc is a registered bank holding company whose wholly-owned banking subsidiary is Columbia State Bank. The company provides a full range of banking services to small and medium sized businesses, professionals, and individuals throughout Washington, Oregon, Idaho, and California. The company's subsidiary Columbia Trust Company is an Oregon trust company that provides agency, fiduciary, and other related trust services with offices in Washington, Oregon, and Idaho. The firm offers various products and services under Personal Banking, Business Banking, and Wealth Management divisions.
<h3>Unraveling the Financial Story of Columbia Banking System</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Columbia Banking System displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 3.73%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 17.63%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Columbia Banking System's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.67%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Columbia Banking System's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.17%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 0.59, Columbia Banking System faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COLB

9 Analysts Assess Columbia Banking System: What You Need To Know

In the preceding three months, 8 analysts have released ratings for ITT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITT#NYSE">ITT</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $160.88, a high estimate of $177.00, and a low estimate of $148.00. Highlighting a 0.54% decrease, the current average has fallen from the previous average price target of $161.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1747864832_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of ITT among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Obin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$170.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Joe Ritchie</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$177.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$171.00</td>
<td>$161.00</td>
</tr>
<tr>
<td>Jeffrey Hammond</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$161.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Vladimir Bystricky</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$150.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$148.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Jeffrey Hammond</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$170.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to ITT. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ITT compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of ITT's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of ITT's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ITT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ITT analyst ratings.</a>
<h2>Discovering ITT: A Closer Look</h2>
ITT began its journey as International Telephone &amp; Telegraph in 1920. Through decades of acquisitions in the mid-1900s, ITT went from manufacturing telephone switching equipment to operating hotels, car rentals, insurance agencies, and bread bakeries. In 1995, the firm split into three separate entities, one of which is the ITT in current operation. After a few more spinoffs in 2011, today ITT Inc. sells automotive, industrial, and aerospace products such as brake pads, seals, pumps, valves, connectors, and regulators. It has operations around the globe with notable exposures to North America, Europe, and Asia.
<h3>Key Indicators: ITT's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: ITT's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 0.26%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: ITT's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.87% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): ITT's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 3.91%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): ITT's ROA stands out, surpassing industry averages. With an impressive ROA of 2.27%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: ITT's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.3.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into ITT Stock: Analyst Perspectives (8 Ratings)

In the preceding three months, 7 analysts have released ratings for GDS Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $44.71, a high estimate of $53.00, and a low estimate of $37.00. This current average reflects an increase of 30.2% from the previous average price target of $34.34. 
<img src="https://www.benzinga.com/files/images/story/2025/1747864824_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of GDS Holdings by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greg Miller</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Greg Miller</td>
<td>Citizens Capital Markets</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Frank Louthan</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Strong Buy</td>
<td>$53.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Edison Lee</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Atkin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$37.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Edison Lee</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$45.00</td>
<td>$27.06</td>
</tr>
<tr>
<td>Frank Louthan</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$53.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to GDS Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of GDS Holdings compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of GDS Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of GDS Holdings's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GDS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on GDS Holdings analyst ratings.</a>
<h2>All You Need to Know About GDS Holdings</h2>
GDS Holdings started as an IT service provider in 2001 then moved to the data center business with its first self-developed data center opening in 2010. The company now develops and operates data centers in China and also builds, operates and transfers data centers for other clients. It offers colocation and managed services and mainly targets hyperscale cloud service customers who take large areas of its data centers or even whole data centers under long-term contracts. It has aggressively raised capital over the past four years for expansion. Its data centers are located predominantly in and around the Tier 1 cities in China and it has also started an expanding into Southeast Asia. GDS listed on the Nasdaq in 2016 and completed a secondary listing in Hong Kong in 2020.
<h3>Understanding the Numbers: GDS Holdings's Finances</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Decline in Revenue: Over the 3M period, GDS Holdings faced challenges, resulting in a decline of approximately -20.14% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: GDS Holdings's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 219.47% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): GDS Holdings's ROE excels beyond industry benchmarks, reaching 20.33%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 5.35%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 1.98, GDS Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: GDS Holdings Through The Eyes Of 7 Analysts

In the current market session, Arch Capital Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>) share price is at $92.85, after a 1.42% drop. Over the past month, the stock went up by 0.37%, but over the past year, it actually fell by 8.91%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1747864822_0.png" alt="Past Year Chart" />

<h3>Arch Capital Group P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 24.43 in the Insurance industry, Arch Capital Group Inc. has a lower P/E ratio of 9.66. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747864822_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

ACGL

Price Over Earnings Overview: Arch Capital Group

Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) has outperformed the market over the past 20 years by 2.76% on an annualized basis producing an average annual return of 11.01%. Currently, Ecolab has a market capitalization of $74.01 billion. 
Buying $100 In ECL: If an investor had bought $100 of ECL stock 20 years ago, it would be worth $800.95 today based on a price of $260.95 for ECL at the time of writing.
<h3>Ecolab's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747864815_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

ESLT

Elbit Systems Announces Public Offering of 1.365M Shares

Nike Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) shares are trading higher in Wednesday&#8217;s after-hours session following a report that the company will sell on Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) for the <a href="https://www.benzinga.com/25/05/45512822/nike-announces-layoffs-in-tech-division-shifts-focus-to-third-party-vendors">first time in six years</a>.
What Happened: According to a <a href="https://www.theinformation.com/articles/nike-sell-amazon-first-time-since-2019">report</a> from The Information, Amazon will start selling Nike products on its e-commerce platform for the first time since 2019. 
The two companies previously worked together before Nike decided to stop selling on Amazon.com, opting to sell direct to customers through its own website. An Amazon spokesperson reportedly confirmed that Amazon will start selling Nike products again with supplies coming directly from Nike. 
A separate report from <a href="https://frontofficesports.com/nike-raising-prices-on-some-products/">Front Office Sports</a> indicates that Nike also plans to raise prices on some of its products. The price increases will reportedly impact shoe and apparel products above $100. 
<h3 class="wp-block-heading">How To Buy NKE Stock</h3>
By now, you're likely curious about how to participate in the market for Nike &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> 
Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
NKE Price Action: <a href="http://benzinga.com/quote/NKE">Nike shares</a> are down about 20% year-to-date. The stock got a lift from the Amazon announcement, last up 2.39% in after-hours, trading at $61.40 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45553121/snowflake-q1-earnings-revenue-eps-beat-estimates-ai-data-cloud-company-sees-25-growth-ahead-shares-climb">Snowflake Q1 Earnings: Revenue, EPS Beat Estimates, AI Data Cloud Company Sees 25% Growth Ahead, Shares Climb</a></li>
</ul>
Photo: Shutterstock.

Contracts

AMZN

Nike Stock Sprints Higher After Hours As Retailer Returns To Amazon: Report

Kaya Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) reported quarterly losses of $(0.04) per share. This is a 300 percent decrease over losses of $(0.01) per share from the same period last year. The company reported $7.05 thousand in sales this quarter.

KAYS

Kaya Holdings Q1 EPS $(0.04) Down From $(0.01) YoY, Sales $7.05K

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 20 years by 4.59% on an annualized basis producing an average annual return of 12.84%. Currently, Molina Healthcare has a market capitalization of $17.31 billion. 
Buying $100 In MOH: If an investor had bought $100 of MOH stock 20 years ago, it would be worth $1,118.60 today based on a price of $319.29 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747863926_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Molina Healthcare Stock In The Last 20 Years

Health care stocks including UnitedHealth Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), Elevance Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) and CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) are tanking in Wednesday's extended trading after the Centers for Medicare &amp; Medicaid Services (CMS) announced a significant expansion of its auditing efforts for <a href="https://www.benzinga.com/content/45529802/unitedhealth-insiders-double-down-is-unh-stock-a-value-play">Medicare Advantage (MA) plans. </a>
The Details: The Centers for Medicare &amp; Medicaid Services said <a href="https://www.cms.gov/newsroom/press-releases/cms-rolls-out-aggressive-strategy-enhance-and-accelerate-medicare-advantage-audits">it will audit</a> all eligible MA contracts for each payment year in newly initiated audits and invest additional resources to expedite the completion of audits in its backlog. 
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/05/45524565/nvidias-1-trillion-comeback-shows-deepseek-no-longer-spooks-wall-street?utm_source=articleShare">Nvidia&#8217;s $1 Trillion Comeback Shows DeepSeek No Longer Spooks Wall Street&nbsp;</a>
"We are committed to crushing fraud, waste and abuse across all federal healthcare programs," said Dr. Mehmet Oz, CMS Administrator.&nbsp;
"While the Administration values the work that Medicare Advantage plans do, it is time CMS faithfully executes its duty to audit these plans and ensure they are billing the government accurately for the coverage they provide to Medicare patients," Dr. Oz added.&nbsp;
The Trump administration will deploy advanced technology, expand the CMS workforce from 40 to 2,000 medical coders and increase its audit volume to all MA plans each year.&nbsp;
CMS also said that its last significant recovery of MA overpayments occurred following the audit of payment year 2007 and estimates suggest MA plans may overbill the government by approximately $17 billion annually.&nbsp;
CMS will now collaborate with the Department of Health and Human Services Office of Inspector General to recover uncollected overpayments identified in past audits.
UNH, ELV, CVS Price Action: After-hours on Wednesday, UnitedHealth stock was down 3.87% at $291.26, Elevance Health stock was down 1.28% at $394.99 and CVS Health shares were down 4.56% at $59.28 at the time of publication.
Read Also:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45506863/trumps-big-beautiful-bill-advances-heres-who-wins-and-loses?utm_source=articleShare">Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Advances: Here&#8217;s Who Wins And Loses&nbsp;</a></li>
</ul>
Image: Shutterstock

Government

Regulations

Health Care

After-Hours Center

Health Care Stocks Like UnitedHealth, CVS Tank On Wednesday: Here's Why

Gartner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) has outperformed the market over the past 20 years by 12.67% on an annualized basis producing an average annual return of 20.92%. Currently, Gartner has a market capitalization of $34.09 billion. 
Buying $100 In IT: If an investor had bought $100 of IT stock 20 years ago, it would be worth $4,469.32 today based on a price of $442.91 for IT at the time of writing.
<h3>Gartner's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747863026_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

Press Releases

Duality Biologics and BioNTech Presented Positive Interim Data for Investigational B7-H3 Antibody-Drug Conjugate BNT324/DB-1311 in Advanced Solid Tumors at the ESMO Asia Congress 2024

BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

BioNTech Completes Acquisition of Biotheus

BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025

BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

Barbara Weber, M.D., Elected to ITM Supervisory Board

BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025

BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025

BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer

BioNTech Announces First Quarter 2025 Financial Results and Corporate Update

RLAY

RVMD

TNGX

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

HC Wainwright & Co.

Citigroup

Morgan Stanley

Canaccord Genuity

BMO Capital

화요일(20일) 백신 관련 주식이 상승세를 보였다. 이는 미국 식품의약국(FDA)에서 공개된 문서에 따르면 해당 기관의 자문위원회가 <a href="https://www.benzinga.com/25/05/45524971/pfizer-stock-is-trading-higher-tuesday-whats-going-on" target="_blank" rel="noopener">이번 주에 회의를 개최할 예정</a>이기 때문이다.
주요 내용: 자문위원회는 2025-2026년 백신 접종 주기에서 업데이트된 코로나19 백신이 LP.8.1 하위 변종을 표적으로 삼아야 하는지 논의할 계획이다. LP.8.1 변이는 이전에 지배적이었던 JN.1 변이에서 파생된 것으로, 최근 CDC 데이터에 따르면 미국 코로나19 확진 사례의 약 70%를 차지하는 것으로 추정된다. 로이터 통신에 따르면 유럽 일부 지역을 포함해 전 세계적으로 확산되고 있다.
FDA 문서에 따르면, 바이러스의 지속적인 진화 때문에 백신 변이주 업데이트가 검토 중이다. LF.7과 XFG와 같은 다른 신종 변이주도 모니터링 중이지만, 현재 LP.8.1이 가장 널리 퍼져 있다. 모더나와 화이자-바이오엔테크는 mRNA 기반 백신을 생산하며, 노바백스는 단백질 기반 대안 백신을 제공한다.
별도의 업데이트에서 FDA는 65세 미만 건강한 성인에 대한 연간 코로나19 부스터 접종에 새로운 임상 시험이 필요하다고 밝혔다. 이는 이번 가을 백신 접종 대상이 고령자와 고위험군으로 제한될 것을 의미한다.
주가 움직임: 화요일 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)주가는 6.06% 상승한 27.99달러에 마감했고, 바이오엔테크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) 주가는 4.01% 상승한 101.72달러에 마감했다.
이미지 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

지난주 가장 저조한 성과를 기록한 대형주는 다음과 같다.
<ol class="wp-block-list">
<li>아겐스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) 주가는 <a href="https://www.benzinga.com//node/45275849" target="_blank" rel="noreferrer noopener">1분기 실적을 발표</a>한 후 15.40% 급락했다.</li>
<li>버텍스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) 주가는 예상을 하회하는 2025년 1분기 수익을 발표한 후 15.20% 하락했으며, 애널리스트들은 <a href="https://www.benzinga.com//node/45236530" target="_blank" rel="noreferrer noopener">목표주가를 수정</a>했다.</li>
<li>서밋 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) 주가는 14.12% 하락했다.</li>
<li>메이크마이트립(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) 주가는 12.96% 급락했다.</li>
<li>리제네론 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) 주가는 12.85% 하락했다. 미국 식품의약국(FDA)은 <a href="https://www.benzinga.com//node/45234032" target="_blank" rel="noreferrer noopener">미국 소비자와 환자를 위한 식품, 필수 의약품 및 기타 의약품을 생산하는 외국 제조 시설의 무작위 검사를 확대할 의사를 밝혔다</a>.</li>
<li>로켓 컴퍼니스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) 주가는 <a href="https://www.benzinga.com//node/45299460" target="_blank" rel="noreferrer noopener">1분기 실적을 발표</a>한 후 11.97% 급락했으며, 예상보다 낮은 2분기 매출 전망을 제시했다.</li>
<li>바이온엔테크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) 주가는 <a href="https://www.benzinga.com//node/45205736" target="_blank" rel="noreferrer noopener">분기 실적을 발표</a>한 후 11.60% 하락했으며, 애널리스트들은 <a href="https://www.benzinga.com/quote/bntx/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 수정</a>했다.</li>
<li>어펌 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) 주가는 11.33% 하락했으며, 회사는 <a href="https://www.benzinga.com//node/45322588" target="_blank" rel="noreferrer noopener">3분기 실적을 발표하고 목표주가를 수정</a>했다.</li>
<li>FNF 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNF#NYSE">FNF</a>) 주가는 <a href="https://www.benzinga.com//node/45266700" target="_blank" rel="noreferrer noopener">1분기 실적을 발표</a>한 후 10.98% 하락했다.</li>
<li>일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) 주가는 지난 주 트럼프 행정부의 <a href="https://www.benzinga.com//node/45233995" target="_blank" rel="noreferrer noopener">국내 의약품 제조 강화를 위한 행정명령</a>에 반응하여 10.81% 하락했다.</li>
<li>오로라 이노베이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) 주가는 <a href="https://www.benzinga.com//node/45300096" target="_blank" rel="noreferrer noopener">1분기 재무 실적을 발표</a>한 후 10.57% 하락했으며 애널리스트들은 목표주가를 수정했다.</li>
<li>도어대시(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) 주가는 부진한 1분기 매출 발표 후 10.52% 하락했으며, <a href="https://www.benzinga.com//node/45264549" target="_blank" rel="noreferrer noopener">애널리스트들은 목표주가를 수정</a>했다.</li>
</ol>
사진 제공: Jonathan Weiss via Shutterstock

CNN 머니 공포·탐욕 지수는 전체 시장 심리가 개선된 모습을 나타냈지만, 지수는 금요일에도 여전히 &#8220;극단적 공포&#8221; 영역에 머물렀다.
미국 주식은 금요일(7일)에 상승 마감했으며, 다우존스 지수는 장중에 200포인트 이상 상승했다. 그러나 지수는 지난주 동안 하락세를 기록했다. S&amp;P 500 지수는 9월 이후 최악의 주간 성적을 기록하며 지난주에 3.1% 하락했다. 다우는 2.4% 하락했으며, 나스닥 종합지수는 3.5% 급락했다.
경제지표 측면에서, 노동통계국이 금요일에 발표한 2월 고용 보고서는 고용이 완만하게 증가했으며 실업률도 약간 상승했음을 나타냈다.
미국 경제는 2월에 151,000개의 일자리를 추가했으며, 이는 1월에 하향 수정된 125,000개보다 증가한 수치지만, 트레이딩 이코노믹스(Trading Economics)의 예상치 160,000개에는 미치지 못했다. 실업률은 예상보다 높게 4.1%로 상승했으며, 이는 예상치인 4.0%를 상회하는 수치다.
제네스코(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCO#NYSE">GCO</a>) 주가는 4분기 재무 실적이 예상보다 저조하게 나타난 후 금요일에 16% 이상 하락했다. 반면 아메리칸 퍼블릭 에듀케이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEI#NASDAQ">APEI</a>) 주가는 예상보다 좋은 분기 재무 실적을 발표한 후 22% 급등했다.
S&amp;P 500 지수 대부분 섹터가 긍정적으로 마감했으며, 유틸리티, 정보기술 및 에너지 섹터가 금요일에 가장 큰 상승폭을 기록했다. 그러나 소비재와 금융 섹터는 전체 시장 추세와 달리 하락헸다.
다우존스는 금요일에 약 223포인트 상승하여 42,801.72포인트로 마감했다. S&amp;P 500은 0.55% 상승하여 5,770.20포인트, 나스닥 종합 지수는 0.70% 상승하여 18,196.22포인트로 금요일 거래를 마쳤다.
투자자들은 오늘 바이오엔테크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), 오라클(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>), 베일 리조트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>)의 실적 발표를 기다리고 있다.
<h3>CNN 비즈니스 공포·탐욕 지수란?</h3>
공포·탐욕 지수는 현재 20.5이며 금요일에도 &#8220;극단적 공포&#8221; 영역에 머물렀다. 이전 수치는 17.8이었다.
공포·탐욕 지수는 현재 시장 심리를 측정하는 지표다. 공포가 높을수록 주가에 압력을 가하고, 탐욕이 높을수록 주가를 상승시킨다는 전제를 바탕으로 한다. 이 지수는 동일한 가중치를 가진 7가지 지표를 기준으로 계산된다. 지수의 범위는 0에서 100까지이며 0은 최대 공포를, 100은 최대 탐욕을 나타낸다.
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

다우 200p 이상 올랐으나 주간 하락 기록: 탐욕 지수는 여전히 '극단적 공포' 영역

월요일(10일) 아침 미국 주식 선물이 하락세를 보이는 가운데, 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다.
<ul>
<li>바이오엔테크 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>): 개장 전 실적을 발표할 예정이며, 애널리스트들은 바이오엔테크의 분기 주당순이익을 58센트, 매출을 11억 5천만 달러로 발표할 것으로 예상하고 있다. 주식은 애프터마켓에서 3.7% 상승한 112.83 달러에 거래되었다.</li>
<li>오라클 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>): 오늘 장 마감 후 실적을 발표할 예정이며, 분기 주당순이익 1.49달러 및 매출 144억 달러가 예상된다. 주식은 애프터마켓에서 0.2% 상승한 155.40달러에 거래되었다.</li>
<li>코그니전트 테크놀로지 솔루션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>): 금요일 애프터마켓 거래에서 행동주의 투자자인 맨틀 리지(Mantle Ridge)가 회사에 10억 달러 이상의 지분을 확보했다는 보도가 나온 후 상승했다. 주식은 애프터마켓에서 4.9% 상승한 87.28 달러에 거래되었다.</li>
</ul>
자세한 내용은 <a href="https://www.benzinga.com/premarket/" target="_blank" rel="noopener">프리마켓 보도</a>를 확인하세요.
<ul>
<li>미션 프로듀스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVO#NASDAQ">AVO</a>): 장 마감 후 실적을 발표할 예정이며, 주당순이익 3센트, 매출 2억 8천 5백만 달러가 예상된다. 주식은 애프터마켓에서 1.2% 상승한 12.10달러에 거래되었다.</li>
<li>베일 리조트 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>): 장 마감 후 실적을 발표할 예정이며, 분기 주당순이익 6.31달러, 매출 11억 4천만 달러가 예상된다. 주식은 애프터마켓에서 0.3% 하락한 157.00달러에 거래되었다.</li>
</ul>
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

CTSH

월요일 주목해야 할 주식: 바이오엔테크, 오라클, 코그니전트, 미션 프로듀스 및 베일 리조트

1월 13일부터 17일까지 지난주에 가장 저조한 성과를 보인 대형주 11개 종목은 다음과 같다.
<ol>
<li>FTAI 애비에이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>): 지난주 35.42% 급락했다. 이는 공매도 전문 회사인 머디 워터스 리서치(Muddy Waters Research)가 회사에 <a href="https://www.benzinga.com//node/43040046" target="_blank" rel="noreferrer noopener">공매도 포지션을 시작했다고 발표</a>한 후 발생했다.</li>
<li>모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>): 지난주 19.38% 급락했다. 회사가 2025년 예상 매출 범위를 15억 달러에서 25억 달러로 업데이트한 것이 <a href="https://www.benzinga.com//node/42946454" target="_blank" rel="noreferrer noopener">애널리스트 추정치 29억 5천만 달러</a>보다 낮았기 때문이다. 모건스탠리는 중립 의견을 유지하고 <a href="https://www.benzinga.com/quote/mrna/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 70달러에서 38달러로 하향 조정</a>했다.</li>
<li>게임스탑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>): 지난주 14.86% 하락했다. 최근 CNBC의 짐 크레이머가 소셜미디어 엑스(X)에 게시한 글에서 투자자들에게 <a href="https://www.benzinga.com//node/43053808" target="_blank" rel="noreferrer noopener">양자 주식으로 재투자할 것을 권유</a>하며 게임스탑에서 얻은 수익을 리제티 컴퓨팅(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>)에 재투자하라고 제안했다.</li>
<li>스냅(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>): 지난주 12.91% 하락했다. 이는 트럼프가 틱톡을 미국 금지에서 구하기 위한 행정명령을 고려하고 있다는 보도가 나온 후 발생한 일이다.</li>
<li>로켓랩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>): 지난주 10.81% 하락했다. 로켓랩은 발다 스페이스 인더스트리(Varda Space Industries)를 위한 두 번째 파이오니어(Pioneer) 우주선이 <a href="https://www.benzinga.com//node/43028933" target="_blank" rel="noreferrer noopener">궤도에서 성공적으로 작동 중이다</a>고 발표했다.</li>
<li>나테라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>): 구겐하임이 <a href="https://www.benzinga.com/quote/ntra/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 170달러에서 200달러로 상향 조정</a>한 것에도 불구하고 지난주 9.51% 하락했다. 회사는 J.P. 모건 헬스케어 컨퍼런스에서 로드맵과 전망을 제공할 예정이다.</li>
<li>일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>): 지난주 9.27% 하락했다. 회사가 2024년 매출 전망을 <a href="https://www.benzinga.com//node/42976923" target="_blank" rel="noreferrer noopener">이전 예상보다 낮게 발표</a>한 후 발생했다.</li>
<li>아이콘(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>): 지난주 9.22% 하락했다. 회사가 2025년 가이던스를 발표했을 때 <a href="https://www.benzinga.com//node/42971328" target="_blank" rel="noreferrer noopener">중간값이 예상치보다 낮았기 때문이다.</a></li>
<li>바이오엔테크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>): 지난주 8.89% 하락했다. 이는 모더나가 2025년 매출 전망을 <a href="https://www.benzinga.com//node/42951363" target="_blank" rel="noreferrer noopener">애널리스트 예상보다 낮게 발표</a>한 후 발생한 일이다.</li>
<li>노보 노디스크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>): 지난주 8.89% 하락했다. 이번 하락은 오젬픽(Ozempic)과 위고비(Wegovy)가 <a href="https://www.benzinga.com//node/43062779" target="_blank" rel="noreferrer noopener">메디케어 약가 협상 목록</a>에 포함되었다는 발표 후 나타났다.</li>
<li>바이오마린 파마슈티컬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>): 지난주 8.68% 급락했다. 회사는 어센디스 파마(Ascendis Pharma A/S)에 대해 유럽 특허 EP 3 175 863 B1 침해로 <a href="https://www.benzinga.com//node/42953403" target="_blank" rel="noreferrer noopener">독일 뮌헨 통합 특허 법원에서 법적 조치를 취했다</a>고 발표했다.</li>
</ol>
사진 제공: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Short Sellers

BMRN

FTAI

ICLR

NTRA

RGTI

RKLB

SNAP

모더나, 게임스탑, 스냅 등 지난주 급락한 대형주 (1월 13일~17일)

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 서밋 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)의 주식이 23.61% 하락했다. 이 회사는 새롭고 잠재적인 최초의 연구용 이중특이성 항체인 아이보네스시맙(ivonescimab)에 대한 데이터가 <a href="https://www.benzinga.com//node/40873837" target="_blank" rel="noreferrer noopener">2024년 ESMO 연례 회의</a>에서 발표되었다고 발표했다.
2. Joint Stock Company Kaspi.kz(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSPI#NASDAQ">KSPI</a>)의 주식이 21.66% 급락했다. 이는 컬퍼 리서치(Culper Research)가 <a href="https://www.benzinga.com//node/40943334" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">이 회사에 대한 공매도 보고서를 발표</a>한 후 주가는 21.66% 하락했다.
3. 바이오마린 파마슈티컬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>)의 주식이 16.74% 하락했다. 이는 경쟁사인 아센디스 파마(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>)의 <a href="https://www.benzinga.com//node/40885653" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">강력한 왜소증 치료제 데이터</a> 발표 이후 발생한 일이다.
4. 리비안 오토모티브(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>)의 주식이 <a href="https://www.benzinga.com//node/40961732" target="_blank" rel="noreferrer noopener">지난주</a> 13.26% 하락했다.
5. 페덱스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>)의 주식은 회사가 예상보다 나쁜 1분기 재무 결과를 보고하고 <a href="https://www.benzinga.com//node/40948046" target="_blank" rel="noreferrer noopener">2025 회계연도 가이던스를 하향 조정</a>한 후 11.08% 하락했다.
6. 바이오엔텍 SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>)의 주식이 9.01% 하락했다. 화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)와 바이오엔텍은 유럽 연합에서 오미크론(omicron) KP.2 적응 <a href="https://www.benzinga.com//node/40956192" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">코로나19 백신</a>에 대해 긍정적인 CHMP 의견을 받았다.
7. 아서 J 갤러거(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>)의 주식이 7.17% 하락했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/ajg/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 목표를 상향 조정</a>한 후 발생한 일이다.
8. 츄이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>)의 주식이 6.97% 하락했다. 이는 회사가 주식 공모와 <a href="https://www.benzinga.com//node/40949015" target="_blank" rel="noreferrer noopener">동시 주식 매입</a>을 발표한 후 발생한 일이다.
9. 노보 노디스크 A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)의 주식은 비만 환자를 대상으로 한 몬루나반트(monlunabant)의 <a href="https://www.benzinga.com//node/40961934" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">중간 단계 연구 결과가 헤드라인</a>을 장식한 후 6.93% 하락했다.
10. 머피 USA(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>)의 주식이 6.90% 하락했다. 이는 JP 모건이 주식 등급을 중립에서 비중축소(Underweight)로 하향 조정했지만 <a href="https://www.benzinga.com/quote/musa/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가를 $415에서 $435로 상향 조정</a>한 후 발생한 일이다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%BD%98%EC%8A%A4%ED%85%94%EB%A0%88%EC%9D%B4%EC%85%98-%EB%B0%8F-%EC%B9%B4%EB%B0%94%EB%82%98%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC/" target="_blank" rel="noopener">콘스텔레이션 및 카바나는 지난주 최고 성과를 보여준 11개 대형주 중 일부 (9월 16일-9월 20일)</a></li>
</ul>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

ASND

CHWY

KSPI

MUSA

RIVN

노보 노디스크, 츄이 및 페덱스는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (9월 15일-9월 21일)

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 서밋 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/40833208" target="_blank" rel="noreferrer noopener">$2억 3,500만</a>의 순수익을 올렸다고 발표한 후 98.32% 급등했다.
2. 바이오엔텍 SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>)의 주식은 GSK가 단순 포진 바이러스 백신 개발을 중단하자 모더나와 바이오엔텍와 같은 다른 경쟁자들에게 길을 열어주면서 지난주 31.77% 상승했다.
3. 앱러빈 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>)의 주식은 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/app/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가를 올린 후</a> 28.38% 상승했다.
4. 츄이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>)의 주식은 펫코 헬스 앤 웰니스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>)의 <a href="https://www.benzinga.com//node/40822147" target="_blank" rel="noreferrer noopener">재무 결과 발표</a>에 동조하는 분위기 속에서 21.37% 상승했다.
5. 브로드컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)의 주식은 일부 반도체 주식의 <a href="https://www.benzinga.com//node/40852990" target="_blank" rel="noreferrer noopener">반등</a>으로 인해 20.81% 상승했다.
6. Arm 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>)의 주식은 레이먼드 제임스(Raymond James)가 주식을 아웃퍼폼(Outperform) 등급으로 분석을 시작하고 <a href="https://www.benzinga.com/quote/arm/analyst-ratings" target="_blank" rel="noreferrer noopener">$160의 목표 주가</a>를 발표한 후 20.50% 상승했다.
7. 마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)의 주식은 회사가 18,300개의 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)을 구매했다고 발표한 후 18.74% 상승했다.
8. 킨로스 골드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGC#NYSE">KGC</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/40788842" target="_blank" rel="noreferrer noopener">그레이트 베어(</a><a href="https://www.benzinga.com//node/40788842" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">Great Bear</a><a href="https://www.benzinga.com//node/40788842" target="_blank" rel="noreferrer noopener">) 프로젝트</a>에 대한 초기 경제 평가를 완료했다고 발표한 후 17.14% 상승했다.
9. 워너 브라더스 디스커버리(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)의 주식은 최근 발표된 차터(Charter)와의 다년간 파트너십으로 인해 지난주 17.10% 상승했다. 이 파트너십은 선형 비디오와 스트리밍 서비스를 통합하여 비디오 번들의 유연성과 가치를 향상시킨다.
10. 버티브 홀딩스, LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>)의 주식은 17.02% 상승했다.
이미지 출처: Chewy
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

$BTC

AVGO

EXAS

FSLR

MSTR

ROKU

WOOF

츄이, 브로드컴 및 ARM은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (9월 8일-9월 14일)

글로벌 시장은 극심한 변동성을 겪고 있으며, <a href="https://www.benzinga.com/markets/equities/24/08/40152271/mohamed-el-erian-grant-cardone-and-matt-weller-warn-of-deepening-global-market-selloff-as-yen-ri" target="_blank" rel="noopener" data-google-interstitial="false">일본의 닛케이 225 지수가 밤새 13% 급락한</a> 이후 월스트리트의 블랙 먼데이는 불가피한 것처럼 보였지만, 주가 지수는 뉴욕 정오 거래를 통해 장 초반 손실을 제한하려고 시도하고 있다.
이 변곡점은 7월의 서비스 부문 활동 조사에서 6월보다 개선된 여건과 예상보다 강한 확장세를 보여 미국 <a href="https://www.benzinga.com/news/econ-s/24/08/40161832/us-services-activity-returns-to-growth-in-july-global-market-selloff-stalls-are-recession-fears-over" target="_blank" rel="noopener" data-google-interstitial="false">경기 침체</a>에 대한 우려가 완화된 이후에 발생했다.
7월에는 ISM 서비스 구매관리자지수(PMI)가 48.8%에서 51.4%로 상승해 예상치인 51% 상승을 뛰어넘는 등 미국 서비스 부문의 기업 심리가 다시 확장세를 보였다.
ISM 데이터가 발표되기 전에 트레이더들은 오스탄 굴스비 시카고 연준 총재가 CNBC 인터뷰에서 모든 것이 논의될 수 있다고 말한 후 회의 중 연준 금리 인하를 추측했다.
이후 이 데이터가 발표되자, CME 그룹의 페드워치(FedWatch) 도구에 따르면 시장에 내재된 50베이시스포인트(bp) 금리 인하 가능성은 100%에서 약 80%로 감소한 반면, 25bp 인하 가능성은 약 0%에서 20%로 증가했다. .
S&amp;P 500은 4% 이상 하락한 5,120포인트에서 개장한 후 오후 12시 30분까지 손실폭을 소폭 줄인 5,233포인트에 거래되었다. 이는 전 날에 비해 2.1% 하락한 것이다.
기술주 중심의 나스닥 100, 다우존스가 추적하는 우량주 그리고 소형주에서도 비슷한 움직임이 관찰되었다.
금리 확률이 바뀌면서 채권 상승이 멈췄고 국채 수익률은 모든 만기에서 상승했다. 2년 만기 국채 수익률은 거래시간 초반 3.65%까지 하락한 뒤 4bp 오른 3.92%에 거래됐다.
인기 있는 iShares 20+Year Treasury Bond ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>)는 7회 연속 상승세를 보인 이후 변동이 없었다.
비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)은 뉴욕에서 오전 9시 30분에 처음으로 15% 하락했지만, 이후 오전 9시 30분부터 오후 12시 30분까지 10% 반등하여 일일 손실률을 5.9%로 줄였다.
원자재는 금과 석유가 각각 1.5%, 1.3% 하락하는 등 전반적으로 하락세를 보였다. 은은 두 달 만에 최악의 세션으로 거의 5% 급락했다.
<h2 class="wp-block-heading">월요일 주요 미국 지수 및 ETF</h2>
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>주요 지수</td>
<td>가격</td>
<td>1일 변동률</td>
</tr>
<tr>
<td>다우존스</td>
<td>38,918.07</td>
<td>-2.1 %</td>
</tr>
<tr>
<td>나스닥 100</td>
<td>18,040.81</td>
<td>-2.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,226.62</td>
<td>-2.2%</td>
</tr>
<tr>
<td>러셀 2000</td>
<td>2,055.96</td>
<td>-2.4%</td>
</tr>
</tbody>
</table><figcaption class="wp-element-caption">동부 표준시 12시 43분 기준 업데이트됨</figcaption></figure>
Benzinga Pro의 데이터에 따르면:
<ul>
<li>SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)는 520.50달러로 2.2% 하락했다.</li>
<li>SPDR Dow Jones Industrial Average(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)는 388.75달러로 2.1% 하락했다.</li>
<li>기술주 중심의 Invesco QQQ Trust Series(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)는 438.40달러로 2.3% 하락했다.</li>
<li>iShares Russell 2000 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>)는 203.26달러로 2.7% 하락했다.</li>
<li>부문별로는, Real Estate Select Sector SPDR Fund(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)가 1.2% 감소로 가장 작은 하락세를 보인 반면, Technology Select Sector SPDR Fund(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)는 2.8% 하락하여 가장 큰 하락세를 보였다.</li>
</ul>
<h2 class="wp-block-heading">월요일의 개별 종목 움직임</h2>
<ul>
<li>켈라노바(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>)의 주가는 비공개 기업인 마즈(Mars)가 프링글스(Pringles) 제조업체를 인수하기 위한 사전 협상을 진행 중이라고 월스트리트 저널(WSJ)이 보도한 후 14% 이상 급등했다.</li>
</ul>
실적에 대한 반응으로 움직인 주식들은 다음과 같다:
<ul>
<li>바이오엔텍 SE(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) (2.54% 하락),</li>
<li>칼라일 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) (8% 하락),</li>
<li>타이슨 푸드(NYSW:TSN) (4% 상승)</li>
</ul>
마감 이후에 실적 발표는은 다음과 같다: 애드트랜 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTN#NASDAQ">ADTN</a>), AVIS 버짓 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>), 다이아몬드백 에너지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>), CSX(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>), 나비타스 반도체(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>), J&amp;J 스낵 푸드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JJSF#NASDAQ">JJSF</a>), 팔란티어 테크놀로지스NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) 및 염 차이나 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NASDAQ">YUMC</a>).
Photo: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

BioNTech

뉴스

에 대한 최신 뉴스 BioNTech (NASDAQ:BNTX) 주식

수요일, 5월 21, 2025

일요일, 5월 11, 2025

월요일, 3월 10, 2025

월요일, 1월 20, 2025

월요일, 9월 23, 2024

일요일, 9월 15, 2024

월요일, 8월 05, 2024

일요일, 6월 23, 2024

일요일, 5월 26, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌